Newsletter
ChrysCapital has acquired a 70.68% stake in listed pharmaceutical trading and distribution company Novartis India. It has also appointed Vikas Gupta as the company's new Chief Executive Officer and Managing Director.
Why it matters: the deal puts one of India's longstanding pharmaceutical businesses under dedicated private equity ownership, with the goal of building a leading branded generics platform.
ChrysCapital has a strong track record of investing in healthcare and plans to use its sector expertise and network to support Novartis India's next leg of growth.
The why: this marks the PE firm’s first majority-controlled investment in India's pharmaceutical sector. But this isn't just about buying one company. The real opportunity is in making bolt-on acquisitions.
ChrysCapital can acquire, or already owns in its portfolio, a ₹300 crore oncology marketer, a ₹500 crore cardiology-focused regional company, a niche sterile injectables business, and a rare-disease distribution platform.
Each acquisition adds scale and strengthens the overall business. A few strategic deals could completely transform Novartis India into a much larger branded generics platform.
Meanwhile, Novartis AG, which began reviewing its India business in February 2024 and signed the sale agreement in February 2026, has now exited completely.
The bigger picture: despite a tariff-related slowdown in the second quarter of 2025, global healthcare private equity activity hit a record, with more than $190 billion in estimated deal value. Deal volume also recorded its second-best year ever.
Much of that record value came from a rise in transactions worth more than $1 billion, although deal activity increased across companies of all sizes.
